AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.900
+0.260 (9.85%)
At close: Aug 21, 2026, 4:00 PM EDT
2.830
-0.070 (-2.41%)
After-hours: Aug 21, 2026, 7:30 PM EDT
AC Immune Employees
As of December 31, 2025, AC Immune had 122 total employees, including 90 full-time and 32 part-time employees. The number of employees decreased by 50 or -29.07% compared to the previous year.
Employees
122
Change (1Y)
-50
Growth (1Y)
-29.07%
Revenue / Employee
$177,619
Profits / Employee
-$437,794
Market Cap
288.34M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 122 | -50 | -29.07% | 90 | 32 |
| Dec 31, 2024 | 172 | 11 | 6.83% | 133 | 39 |
| Dec 31, 2023 | 161 | 5 | 3.21% | 133 | 28 |
| Dec 31, 2022 | 156 | 7 | 4.70% | 126 | 30 |
| Dec 31, 2020 | 149 | 17 | 12.88% | 125 | 24 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Cellectis | 229 |
| Niagen Bioscience | 117 |
| Compugen | 75 |
| Precision BioSciences | 67 |
| Sionna Therapeutics | 59 |
| Pyxis Oncology | 56 |
| Sol-Gel Technologies | 28 |
ACIU News
- 2 days ago - AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 - GlobeNewsWire
- 11 days ago - AC Immune receives fast track designation, clearance for ACI-7104 IND - TheFly
- 17 days ago - AC Immune First Half 2026 Financial and Corporate Update - GlobeNewsWire
- 6 weeks ago - AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - GlobeNewsWire
- 7 weeks ago - AC Immune announces interim data from first three cohorts of ABATE trial - TheFly
- 7 weeks ago - AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease - GlobeNewsWire
- 2 months ago - AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease - GlobeNewsWire
- 2 months ago - AC Immune Slides: Investor presentation - Filings